Early medical therapy for acute laryngeal injury (ALgI) following endotracheal intubation: a protocol for a prospective single-centre randomised controlled trial

• Published in: BMJ open Vol. 9; no. 7; p. e027963
• Main Authors: Lowery, Anne S, Kimura, Kyle, Shinn, Justin, Shannon, Chevis, Gelbard, Alexander
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.07.2019; BMJ Publishing Group
• Subjects: Antibiotics; Chronic obstructive pulmonary disease; Clinical significance; Collagen; Cytokines; Dyspnea; Ear, Nose and Throat/Otolaryngology; Evidence-based medicine; Extracellular matrix; Growth factors; Inflammation; Intensive care; Intervention; Intubation; Patients; Quality of life; Questionnaires; Respiratory failure; Trauma; Ventilators; laryngotracheal stenosis; medical management; acute laryngeal Injury; post-icu dyspnea
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2018-027963

IntroductionRespiratory failure requiring endotracheal intubation accounts for a significant proportion of intensive care unit (ICU) admissions. Little attention has been paid to the laryngeal consequences of endotracheal intubation. Acute laryngeal injury (ALgI) after intubation occurs at the mucosal interface of the endotracheal tube and posterior larynx and although not immediately manifest at extubation, can progress to mature fibrosis, restricted glottic mobility and clinically significant ventilatory impairment. A recent prospective observational study has shown that >50% of patients intubated >24 hours in an ICU develop ALgI. Strikingly, patients with AlgI manifest significantly worse subjective breathing at 12 weeks. Current ALgI treatments are largely surgical yet offer a marginal improvement in symptoms. In this study, we will examine the ability of a postextubation medical regime (azithromycin and inhaled budesonide) to improve breathing 12 weeks after ALgI. Methods and analysisA prospective, single-centre, double-blinded, randomised, control trial will be conducted at Vanderbilt Medical Center. Participants will be recruited from adult patients in ICUs. Participants will undergo a bedside flexible nasolaryngoscopy for the identification of ALgI within 72 hours postextubation. In addition, participants will be asked to complete peak expiratory flow measurements immediately postintubation. Patients found to have ALgI will be randomised to the placebo control or medical therapy group (azithromycin 250 mg and budesonide 0.5 mg for 14 days). Repeat peak expiratory flow, examination of the larynx and patient-reported Clinical COPD (chronic obstructive pulmonary disease) Questionnaire, Voice Handicap Index and 12-Item Short Form Health Survey questionnaires will be conducted at 12 weeks postextubation. Consented patients will also have patient-specific, disease-specific and procedure-specific covariates abstracted from their medical record.Ethics and disseminationThe Institutional Review Board (IRB) Committee of the Vanderbilt University Medical Center has approved this protocol (IRB #171066). The findings of the trial will be disseminated through peer-reviewed journals, national and international conferences.Trial registration number NCT03250975